Helsinn to co-support a satellite symposium on current and emerging treatments of Acute Myeloid Leukemia (AML) at 24th European Hematology Association (EHA) Congress


You May Also Like

Helix BioPharma Corp. Announces Fiscal 2018 Year-End Results

RICHMOND HILL, Ontario, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: ...

Progenics Pharmaceuticals Announces Third Quarter 2018 Financial Results And Business Update

AZEDRA® (iobenguane I 131) Approved by U.S. Food and Drug Administration (FDA)AZEDRA U.S. Launch Progressing ...